AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00882804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemin infusion
Description: Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in \~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
Study NCT00882804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: 25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
Study NCT01367626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: 2.5 mg tablet
Study NCT04554563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability training
Description: 20 sessions of specific core stability exercise with no external loading.
Study NCT03857425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridum Butyricum Capsule
Description: Clostridum Butyricum Capsule 3\*420mg,twice daily for 8 weeks
Study NCT03857425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Coagulans Tablets
Description: Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
Study NCT03857425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets
Description: Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
Study NCT03905928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Containing ECIG with tobacco flavor
Description: Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a tobacco flavor.
Study NCT03905928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Containing ECIG with Strawberry Vanilla Flavor
Description: Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a strawberry vanilla flavor.
Study NCT03905928 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ECIG with Tobacco Flavor
Description: Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a tobacco flavor.
Study NCT03905928 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ECIG with Strawberry Vanilla Flavor
Description: Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a strawberry vanilla flavor.
Study NCT03605108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: • Probiotic fomula per capsule:~* 2 Billion CFUs~* HU36 - 30 mg~* HU58 - 20 mg~* Bacillus clausii -25 mg~* Bacillus coagulans 10B - 35 mg~* Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose.
Study NCT03605108 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour only
Study NCT00302068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Aerobic Exercise
Description: Supervised aerobic exercise, three times per week, for 16 weeks.
Study NCT00302068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline (Zoloft), daily, for 16 weeks.
Study NCT00302068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill.
Description: Placebo pill, daily, for 16 weeks.
Study NCT00728273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: worm treatment and multiple micronutrient fortified biscuits
Description: A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin.
Study NCT02764593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Epidermal Growth Factor Receptor (EGFR) antagonist
Study NCT02764593 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: High-precision radiotherapy
Study NCT02806882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: 600mg IV infusion
Study NCT00640354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated external defibrillator
Description: Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient
Study NCT00640354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual defibrillator
Description: Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
Study NCT01589211 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: Brief advice of about 10 min accompanied by self-help material
Study NCT01589211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compact cessation course
Description: Compact cessation course on the basis of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Group setting. 2 x 120 min.
Study NCT01589211 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard cessation course
Description: Cessation course over 6 dates. Group setting.
Study NCT02846142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428
Study NCT02846142 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02846142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ethinyl estradiol and levonorgestrel
Study NCT02846142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol and levonorgestrel
Study NCT02846142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinyl estradiol and levonorgestrel
Study NCT00720629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visilizumab
Description: 3 mg/m\^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).
Study NCT00720629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
Study NCT00720629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 15 mg/m\^2 intravenously (IV) on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
Study NCT00720629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithymocyte globulin (ATG)
Description: 1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.
Study NCT00720629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: 0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
Study NCT00720629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 15 mg/m\^2 IV on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
Study NCT01474265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 0.5-2 mg per day, oral use
Study NCT01474265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-2 tablets per day, oral use
Study NCT01474265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette TX
Description: 10-15 mg per day, transdermal use (patches)
Study NCT00935116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib
Description: G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery
Study NCT02077140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDT-10013
Study NCT02077140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care for pain
Study NCT04040036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children watch applications by wearing the virtual headset during the blood draw.
Description: wearing the virtual headset
Study NCT04982861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime Trihydrate 100 mg/5 mL Dry Syrup
Description: Participants received a single dose of 5 mL of cefixime dry syrup with 240 mL of water
Study NCT04982861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suprax 100 MG in 5 mL Oral Suspension
Description: Participants received a single dose of 5 mL of Suprax with 240 mL of water
Study NCT03166722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: SpO2 and HR monitoring and routine treatment during immediate transition
Study NCT03166722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study group
Description: Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring
Study NCT00570063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-02545920
Description: Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days
Study NCT00570063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
Study NCT04857528 — intervention group
Intervention type: RADIATION
Intervention: Radiation Treatment With or Without Chemotherapy
Description: Standard care radiation treatment.
Study NCT04857528 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Researchers will collect blood samples from participants before, during and after radiation treatment. Approximately 6 teaspoons of blood will be collected each time blood is drawn.
Study NCT04857528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HPV Genotyping (HPV DNA Test)
Description: A test used to detect the type of HPV DNA found in the participant's blood and tumor tissue samples.
Study NCT04857528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Testing Archival Tumor Tissue
Description: Tumor tissue will be tested in a lab for all cervical cancer participants and some participants with anal cancer as assessed by the lead study doctor. This tumor tissue sample will be from a previous biopsy that the participant received before the study per standard care; no new biopsy will be required for this study.
Study NCT04857528 — intervention group
Intervention type: OTHER
Intervention: Physical Exam
Description: A physical exam will be given 12 months after radiation treatment. This physical exam may also include an anoscopy (a procedure to examine the anus using a device inserted into the anus) or sigmoidoscopy (a procedure that looks at the rectum and lower part of the colon using a device inserted into the anus).
Study NCT04857528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Positron Emission Tomography Scan (PET Scan)/ Computed Tomography Scan (CT Scan)
Description: Tests that use computers and/or rotating x-rays to scan/create images of the body.
Study NCT03036657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAC acupuncture needles
Description: Sterile single-use MAC acupuncture needles (0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea. Used for Manual Acupuncture~Used for: Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min
Study NCT03036657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrostimulator 6c.Pro, Pantheon Research, Venice, CA
Description: Electrostimulator used for delivery or Low-Frequency or High-Frequency Electroacupuncture~Used for Interventions:~Low-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min AND High-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min
Study NCT03207776 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
Study NCT01684202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.
Study NCT03207776 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: COPD Clinical Pathway
Description: A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services.
Study NCT00025025 — intervention group
Intervention type: OTHER
Intervention: sample testing
Study NCT01159730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201 or Placebo
Study NCT01159730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VB-201 or Placebo
Study NCT02058069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Arm Assisted Total Knee Arthroplasty
Description: The total knee implant system used for this study was the Kinetis implant system (MAKO Surgical Corp.).
Study NCT01573585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The Usual Care program will consist of 2 sessions a week for 45 minutes for a 6 week duration.
Study NCT01573585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAST protocol
Description: The Fast muscle activation and Stepping Training (FAST protocol) will be exercises emphasizing speed, small squats and protective steps, that will be progressed. This program will be 2 sessions a week for 45 minutes for 6 weeks in duration.
Study NCT00293787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study NCT00293787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timolol Vehicle
Description: Placebo
Study NCT00293787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% Ophthalmic Solution (XALATAN)
Description: Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
Study NCT00293787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Ophthalmic Solution 0.5%
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
Study NCT01668745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Early measles vaccine
Study NCT00987532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent-focused intervention
Description: The core of the parent-focused intervention is a menu of 15 easy to realize project ideas to promote the everyday physical activity of children and families. The 15 ideas are presented to the parents and teachers via a webpage, a printed book and a film. During a face-to-face meeting, parents and teachers are guided into discussions of their own preschool environment's and community's physical activity shortcomings and encouraged to generate their own ideas of how to enhance the physical activity of their families and preschools. Over the course of three structured follow-up meetings, parents and teachers are instructed to choose maximally 3 to 4 ideas from either the menu or the network's own ideas, and then are empowered to realize and implement them together.
Study NCT00987532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: twice weekly gym lessons
Description: twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
Study NCT00987532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: twice weekly gym lessons
Description: twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
Study NCT04507464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention
Description: Participants will wear a Fitbit that has been programmed to deliver a notification (a buzz) when activity has ceased for more than 10 minutes. They will receive suggestions on their Illumivu mEMA smartphone app on how to replace sitting time with PA such as standing up 5 times or taking 20 steps, or even performing a short (20 seconds) preferred dance routine. Fitbit data will be captured in real-time via the iCardia platform. Participants will receive reminders from their smartphones to enter real-time feedback on activity options selected and how successful they were in adopting the option. These data will allow tracking of underlying preferences for behaviors and to tailor the program accordingly.
Study NCT02548832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine 1500 mg, each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner.
Study NCT02548832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: Bezafibrate capsule 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner.
Study NCT02548832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine plus Bezafibrate
Description: Berberine 1500 mg each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner.~Bezafibrate 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner.
Study NCT00191308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
Study NCT00191308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
Study NCT00191308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Non-Small Cell Lung Cancer (NSCLC) surgery
Description: All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
Study NCT01433172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phase I - GM.CD40L.CCL21 Vaccinations
Description: This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase I: Participants receive the GM.CD40L.CCL21 vaccine in a standard 3+3 design.
Study NCT01433172 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase II - GM.CD40L cells Vaccinations
Description: Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 10\^6 irradiated H1944 tumor cells, 7.5 X 10\^6 irradiated H2122 cells, and containing 15 X 10\^6 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.